Pseudomonas aeruginosa biofilms in cystic fibrosis (Q28299966)

New concepts of the pathogenesis of cystic fibrosis lung disease

Europe PubMed Central

title

Pseudomonas aeruginosa biofilms in cystic fibrosis (English)

0 references

main subject

Pseudomonas aeruginosa

0 references

0 references

0 references

1

Niels Høiby

0 references

Oana Ciofu

series ordinal

2

object named as

Oana Ciofu

0 references

Thomas Bjarnsholt

series ordinal

3

object named as

Thomas Bjarnsholt

0 references

language of work or name

English

0 references

publication date

November 2010

0 references

published in

Future Microbiology

0 references

volume

5

0 references

issue

11

0 references

page(s)

1663-74

0 references

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Lower airway inflammation in infants with cystic fibrosis detected by newborn screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Lower airway inflammation in infants and young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Pulmonary oxidative stress response in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Investigation of the algT operon sequence in mucoid and non-mucoid Pseudomonas aeruginosa isolates from 115 Scandinavian patients with cystic fibrosis and in 88 in vitro non-mucoid revertants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Two distinct loci affecting conversion to mucoidy in Pseudomonas aeruginosa in cystic fibrosis encode homologs of the serine protease HtrA

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Pharmacokinetics of inhaled colistin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Inducible nitric oxide synthase (NOS II) is constitutive in human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Neutrophil recruitment to the lungs during bacterial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Detecting early structural lung damage in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Biofilm formation by the small colony variant phenotype of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Adaptive radiation in a heterogeneous environment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Static growth of mucoid Pseudomonas aeruginosa selects for non-mucoid variants that have acquired flagellum-dependent motility

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

The causes of Pseudomonas diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Comparison of the in vitro and in vivo response to inhaled DNase in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Dynamic interactions of biofilms of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Persister cells and tolerance to antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Antibiotic resistance of bacterial biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Mathematical model of beta-lactam penetration into a biofilm of Pseudomonas aeruginosa while undergoing simultaneous inactivation by released beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Constitutive high expression of chromosomal beta-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal beta-lactamase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Increased mutability of Pseudomonas aeruginosa in biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Early intervention and prevention of lung disease in cystic fibrosis: a European consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Early rise of anti-pseudomonas antibodies and a mucoid phenotype of pseudomonas aeruginosa are risk factors for development of chronic lung infection--a case control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Eradication of early Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Screening for quorum-sensing inhibitors (QSI) by use of a novel genetic system, the QSI selector

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Extracellular DNA and F-actin as targets in antibiofilm cystic fibrosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Avidity of anti-P aeruginosa antibodies during chronic infection in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Antibodies against beta-lactamase can improve ceftazidime treatment of lung infection with beta-lactam-resistant Pseudomonas aeruginosa in a rat model of chronic lung infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

Small-Colony Variants of Pseudomonas aeruginosa in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB.10.125

21 January 2018

Identifiers

DOI

10.2217/FMB.10.125

1 reference

Consolidated OpenCitations Corpus – April 2017

577208

577208

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference